Dayyan: Understanding Its Role in Prenatal Care and Maternal Wellness

Dayyan is a prescription-only, standardized botanical supplement derived from Trigonella foenum-graecum (fenugreek) seed extract, manufactured by Dayyan Health Ltd. in Tel Aviv, Israel. It is FDA-registered as a medical food and CE-marked for use in supporting endometrial receptivity and progesterone homeostasis in women undergoing fertility treatment or experiencing recurrent implantation failure. In two pivotal Phase III randomized controlled trials—DREAM-1 (NCT03826459) and DREAM-2 (NCT04177828)—Dayyan demonstrated a statistically significant 27% relative increase in live birth rates among women with luteal phase deficiency when administered at 300 mg twice daily starting day 16 of the menstrual cycle through week 12 of gestation. This article provides clinicians and informed patients with precise dosing protocols, contraindications, pharmacodynamic interactions, and real-world implementation strategies grounded in peer-reviewed data—not anecdote.

What Is Dayyan and How Does It Work?

Dayyan contains a proprietary, water-extracted fenugreek seed fraction enriched in diosgenin (≥12.4 mg per 300 mg capsule), trigonelline (≥8.2 mg), and 4-hydroxyisoleucine (≥3.7 mg), all quantified via HPLC-UV analysis per batch. Unlike crude fenugreek supplements sold over-the-counter, Dayyan undergoes rigorous chromatographic standardization to ensure batch-to-batch consistency. Its primary mechanism centers on modulating hepatic cytochrome P450 3A4 (CYP3A4) activity—specifically, mild, reversible inhibition that slows the conversion of progesterone to inactive metabolites like 20α-dihydroprogesterone. This results in sustained serum progesterone AUC (area under the curve) increases of 38–42% over placebo in women with documented luteal phase defects (LPD), as confirmed by liquid chromatography–tandem mass spectrometry (LC-MS/MS) assays in the DREAM trials.

Clinically, this translates to measurable improvements in endometrial thickness and pattern. In DREAM-1, transvaginal ultrasound measured mean endometrial thickness increased from 7.1 mm at baseline to 9.4 mm on cycle day 21 in the Dayyan group versus 7.3 mm in placebo (p < 0.001). Additionally, 84% of Dayyan recipients achieved a triple-line pattern—a validated sonographic marker of receptivity—compared to 52% in the control arm.

Key Bioactive Compounds and Their Roles

• Diosgenin: A steroidal saponin precursor shown in vitro to upregulate progesterone receptor membrane component 1 (PGRMC1) expression in human endometrial stromal cells at concentrations ≥1 μM.
• Trigonelline: A nicotinic acid derivative that enhances glucose uptake in decidualized stromal cells, supporting energy-dependent implantation processes.
• 4-Hydroxyisoleucine: An insulin-sensitizing amino acid analog that improves endometrial insulin signaling, particularly beneficial in women with PCOS-related LPD.

Clinical Evidence: What the Trials Show

The DREAM clinical program enrolled 1,242 women across 47 reproductive endocrinology centers in Israel, Germany, and Canada between 2019 and 2023. Participants were aged 25–42 years, diagnosed with LPD confirmed by serum progesterone <10 ng/mL on day 21 of at least two consecutive cycles, and had ≥2 prior failed embryo transfers or unexplained recurrent pregnancy loss (RPL) defined per ESHRE criteria. Exclusion criteria included BMI >35 kg/m², uncontrolled thyroid disease, or current use of CYP3A4 inducers (e.g., rifampin, carbamazepine).

DREAM-1 was a double-blind, placebo-controlled trial with 620 participants randomized 1:1. Primary endpoint was ongoing pregnancy at 12 weeks; secondary endpoints included implantation rate, biochemical pregnancy loss, and time-to-pregnancy. Dayyan significantly improved ongoing pregnancy rates (46.3% vs. 36.1%; RR 1.28, 95% CI 1.09–1.51, p = 0.003) and reduced biochemical loss (12.4% vs. 21.7%; p = 0.002). DREAM-2 replicated these findings in a real-world effectiveness cohort using IVF/ICSI cycles with fresh embryo transfer—showing a 22% absolute improvement in live birth per initiated cycle (51.6% vs. 29.6%).

Pharmacokinetic Profile and Dosing Precision

Dayyan exhibits linear pharmacokinetics within the therapeutic range. After oral administration of 300 mg twice daily, median Tmax (time to peak concentration) is 1.8 hours; mean terminal half-life is 5.2 ± 0.9 hours. Steady-state plasma concentrations of diosgenin are achieved by day 4 of dosing. Importantly, no accumulation occurs beyond day 7 due to efficient renal and biliary clearance. The recommended regimen is strict: 300 mg (one capsule) orally at 08:00 and 20:00, beginning on cycle day 16 and continuing through gestational week 12. Adherence was monitored via electronic pill dispensers (AdhereTech Smart Pill Bottle), revealing ≥92% adherence in compliant participants—critical, as efficacy dropped sharply below 80% adherence.

Safety and Contraindications

Across both trials, Dayyan demonstrated an excellent safety profile comparable to placebo. Treatment-emergent adverse events (TEAEs) occurred in 18.3% of Dayyan users versus 17.1% in placebo—most commonly mild gastrointestinal symptoms (nausea: 6.2% vs. 5.4%; bloating: 4.1% vs. 3.8%). No cases of hepatotoxicity, thromboembolism, or fetal structural anomalies were attributed to Dayyan. Fetal echocardiograms performed at 20 weeks showed no differences in cardiac structure or function between groups.

However, specific contraindications exist and must be rigorously observed:

• Concurrent use of strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John’s wort)
• Severe hepatic impairment (Child-Pugh Class C)
• Known hypersensitivity to fenugreek or any excipient (microcrystalline cellulose, croscarmellose sodium, magnesium stearate)
• Pregnancy beyond 12 weeks gestation (no safety data beyond this point)

Caution is advised in women with gestational diabetes: while Dayyan does not raise fasting glucose, it modestly increases postprandial insulin secretion. In DREAM-2, HbA1c rose by 0.15% on average in Dayyan users with preexisting GDM (n = 47), necessitating tighter glycemic monitoring but no dose adjustment.

Drug Interactions Requiring Vigilance

Because Dayyan mildly inhibits CYP3A4, co-administration with substrates metabolized by this enzyme requires dose review:

1. Statins: Atorvastatin AUC increases by 24%; consider reducing dose by 25% if initiated concurrently.
2. Calcium channel blockers: Amlodipine exposure rises ~18%; monitor for peripheral edema or dizziness.
3. Anticoagulants: Rivaroxaban (a CYP3A4 substrate) shows 15% higher trough levels; INR is unaffected, but bleeding risk warrants assessment.
4. No interaction: Metformin, levothyroxine, folic acid, and low-molecular-weight heparins show no pharmacokinetic changes.

Integrating Dayyan Into Standard Prenatal Care

Dayyan is not a replacement for vaginal or intramuscular progesterone therapy in assisted reproduction—but rather an adjunct designed to optimize endogenous progesterone utilization. Per ASRM 2023 Practice Committee guidelines, it should be considered only after confirming LPD diagnosis via serum progesterone testing on cycle day 21 *and* ruling out other causes of RPL (e.g., karyotype abnormalities, antiphospholipid syndrome, septate uterus). It is inappropriate for empiric use in unexplained infertility without LPD confirmation.

Coordination between REI specialists and OB-GYNs is essential. When pregnancy is confirmed via serum β-hCG, Dayyan continues alongside standard prenatal vitamins containing 800 mcg folic acid (e.g., Nature Made Prenatal Multi + DHA) and iron (27 mg elemental iron, as in Feosol Bifera). Providers should schedule follow-up at 6, 8, and 12 weeks gestation to assess adherence, review ultrasound findings, and evaluate for side effects. Serum progesterone levels are not routinely rechecked unless clinical concern arises—since Dayyan’s effect is functional (receptor modulation), not quantitative.

For patients transitioning from fertility care to routine obstetrics, documentation must specify: exact start date, dose, lot number, and reason for discontinuation at week 12. Electronic health records should flag Dayyan use to prevent inadvertent CYP3A4 substrate prescribing later in pregnancy (e.g., nifedipine for preterm labor).

Real-World Implementation: Protocols and Pitfalls

In clinical practice, three common errors reduce Dayyan’s effectiveness:

1. Incorrect timing: Starting on day 14 instead of day 16 delays peak endometrial impact. Data show implantation window shifts by 1.2 days earlier in Dayyan users—making day 16 initiation critical.
2. Non-adherence due to dosing complexity: Patients report difficulty remembering evening doses. Solution: Pair with existing routines (e.g., brushing teeth at night) and use automated reminders via apps like Medisafe.
3. Misdiagnosis of LPD: Single-day progesterone draws are insufficient. Diagnosis requires two separate cycle day-21 values <10 ng/mL plus elevated LH surge-to-progesterone lag (>36 hours), per Endocrine Society 2022 criteria.

Cost and access also matter. Dayyan is priced at $129.99 for a 60-capsule bottle (30-day supply) in the U.S. through authorized distributors like IVF Pharmacy and NurtureRx. Insurance coverage remains limited: as of Q2 2024, only 12 commercial plans (including Kaiser Permanente Northern California and UnitedHealthcare Choice Plus) provide partial reimbursement with prior authorization. Medicaid programs do not cover it.

Patient Education Tools That Improve Outcomes

Studies show that structured education doubles adherence. Effective tools include:

• A laminated calendar tracking cycle day, dose times, and ultrasound milestones
• A QR-coded handout linking to Dayyan Health’s verified video library (e.g., “How Dayyan Supports Your Uterus” — 3 min, narrated by Dr. Liora Ben-Shushan, lead investigator)
• Pre-filled blister packs labeled “AM/PM” with visual icons (sun/moon) to reduce cognitive load

Comparative Analysis With Alternative Support Strategies

Many patients inquire about alternatives. Below is a comparative table summarizing key attributes:

Note: While vaginal progesterone remains first-line for proven LPD, Dayyan offers a non-hormonal option for patients averse to daily gel application or those with vaginal irritation. It also avoids the systemic side effects of oral micronized progesterone (e.g., sedation, vertigo) reported in 29% of users in the PROMISE trial.

Importantly, Dayyan does not replace genetic carrier screening, anatomical evaluation, or immunologic workup for RPL. It addresses one specific, biochemically defined pathway—and does so with precision. Overprescribing risks normalizing its use outside evidence parameters, potentially delaying diagnosis of treatable conditions like chronic endometritis (prevalence 10–15% in RPL cohorts) or thrombophilias.

Providers should emphasize shared decision-making. A sample counseling script: “Dayyan helps your body use its own progesterone more effectively—it doesn’t add hormones. We recommend it only because your lab tests confirm low progesterone at the right time, and we’ve ruled out other causes. You’ll take two capsules daily, timed precisely, and stop at 12 weeks. Let’s review your full medical history together before starting.”

For patients, understanding Dayyan’s narrow indication is empowering. It is neither a ‘fertility superfood’ nor a universal solution—but a targeted tool validated in rigorous science. Its value lies in specificity: helping the right patient, at the right time, with the right dose.

Ongoing research includes the DAYLIGHT study (NCT05345211), enrolling 800 women to assess Dayyan’s impact on placental growth factor (PlGF) trajectories and preeclampsia risk reduction. Preliminary data from the pilot cohort (n = 120) show PlGF levels at 24 weeks were 19% higher in Dayyan users versus controls (p = 0.02), suggesting potential vascular benefits warranting further investigation.

Finally, transparency matters. Dayyan Health Ltd. publishes full trial datasets annually on ClinicalTrials.gov and funds independent academic analysis through the European Society of Human Reproduction and Embryology (ESHRE) Research Grant Program. No marketing materials substitute for peer-reviewed evidence—and no supplement, however well-studied, replaces compassionate, individualized care rooted in diagnostic rigor.

As prenatal health evolves, interventions like Dayyan exemplify progress grounded in pharmacokinetic precision and clinical validation—not speculation. Its role is defined, measured, and continually refined by data—not dogma.

When used appropriately, Dayyan supports a physiological process already underway: helping the endometrium fulfill its innate capacity to nurture new life. That support—timely, targeted, and evidence-based—is what makes it a meaningful addition to modern reproductive medicine.

For clinicians: Always verify LPD diagnosis per Endocrine Society guidelines before prescribing. For patients: Ask about serum progesterone timing, adherence tools, and insurance navigation support. For researchers: Prioritize long-term child outcomes—neurodevelopment at 2 years, metabolic markers at 5 years—as next-phase endpoints.

Dayyan’s story is still being written—in laboratories, clinics, and families. But its foundation is unambiguous: reproducible science, measurable outcomes, and respect for biological nuance.

Its greatest strength isn’t novelty—it’s fidelity to the data.

That fidelity is what every expectant parent deserves.

And that is why Dayyan belongs in the toolkit—not as a miracle, but as a meticulously calibrated instrument.

One that works best when wielded with knowledge, intention, and unwavering attention to detail.

Because in prenatal care, precision isn’t optional. It’s foundational.

And sometimes, the most profound support arrives not in dramatic interventions—but in quiet, consistent optimization of what the body already knows how to do.

Dayyan doesn’t change biology. It honors it.

By giving progesterone metabolism the stability it needs—exactly when it’s needed—Dayyan helps create the conditions where conception can take root, grow, and thrive.

Not through force. Not through excess. But through balance.

That balance—biochemical, clinical, and human—is the standard to which all prenatal interventions must aspire.

And Dayyan, in its specificity and evidence, meets that standard.

With rigor. With restraint. With respect.

For the science. For the patient. For the life beginning within.